Technology evaluation: TriGem, Titan.
Titan (formerly Trilex) is developing TriGem, a monoclonal antibody directed against I17, for the potential treatment of advanced cancers that express the GD2 ganglioside, including melanoma, small-cell lung cancer, neuroblastoma and sarcoma. Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996.
Razis
Evangelia
E
First Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece.
Fountzilas
George
G
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000096:biosynthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000276:immunology* / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007167:Immunotherapy; D008252:Macaca fascicularis; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D051379:Mice; D011565:Psoriasis / Q000276:immunology* / Q000628:therapy*; D011817:Rabbits
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; C475847:monoclonal antibody TriGem